The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 19 April 2005, www.theannals.com, DOI 10.1345/aph.1E504.
The Annals of Pharmacotherapy: Vol. 39, No. 6, pp. 1024-1028. DOI 10.1345/aph.1E504
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sicard, D. A
Right arrow Articles by Taylor, J. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sicard, D. A
Right arrow Articles by Taylor, J. R

DIABETES

Comparison of Point-of-Care HbA1c Test versus Standardized Laboratory Testing

Devin A Sicard, PharmD

Primary Care Resident, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, FL

James R Taylor, PharmD CDE

Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Florida

Reprints: Dr. Taylor, Department of Pharmacy Practice, College of Pharmacy, University of Florida, HPNP Bldg., PO Box 100486, Gainesville, FL 32610-0486, fax 352/273-6242, jtaylor{at}cop.ufl.edu

BACKGROUND: Glycosylated hemoglobin (HbA1c) evaluation is an accepted standard of care for assessing diabetes control. Point-of-care HbA1c monitors are relatively new, and there are few published data on their accuracy.

OBJECTIVE: To compare a point-of-care HbA1c monitor with standardized laboratory testing.

METHODS: Twenty-three patients who had type 1 or 2 diabetes were identified from our pharmacy-run diabetes clinic at a primary care clinic as needing HbA1c evaluation based on the American Diabetes Association guidelines. All patients with diabetes who attended our clinic were invited to participate in the study. Patients were required to obtain both a standardized laboratory HbA1c evaluation and a point-of-care A1c Now value within a week of each other. An analysis evaluating both clinical and statistical significance was completed at the end of the study.

RESULTS: The A1c Now monitor showed good correlation (r = 0.758) to the standardized laboratory test. We found that the most accurate A1c Now values were within a range of 6-8%. One patient's value would have resulted in a different clinical decision if the decision were based on the A1c Now value.

CONCLUSIONS: It appears that A1c Now may provide adequate accuracy and be useful for some patients. The monitor would be most beneficial for patients who cannot obtain standardized laboratory values secondary to either financial or transportation constraints. However, the decision to make adjustments in therapy should not be based solely on the A1c Now point-of-care result.

Key Words: diabetes, hemoglobin A1c, point-of-care

Published Online, April 19, 2005. www.theannals.com, DOI 10.1345/aph.1E504





homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.